No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Nezha Craze Sweeps the City Wai Yuen Tong Proudly Sponsors Broadcast of "Nezha: The Demon Child Comes Into the World" on Jade Channel
The Nezha craze sweeps the city with WAI YUEN TONG as the honored sponsor of the free broadcast of "Nezha: Birth of the Demon Child" on Jade Channel.
Hong Kong, February 27, 2025 /PR Newswire/ -- WAI YUEN TONG (0897.HK), a pioneer in the Traditional Chinese Medicine industry in Hong Kong, announced an honorary title sponsorship for the TVB Jade channel's screening of the movie "Ne Zha" (Ne Zha 1) at 8 PM on February 28. This film will provide viewers with an opportunity to relive the classic and experience the current Ne Zha craze. With the movie "Ne Zha: The Devil's Birth" (Ne Zha 2) achieving unprecedented success globally, becoming the first film in mainland China's history to surpass 10 billion yuan at the box office, revisiting "Ne Zha 1" will allow the audience to gain a deeper understanding of this legendary character and prepare for the upcoming sequel.
Wai Yuen Tong Medicine Holdings Limited (HKG:897) Surges 29% Yet Its Low P/S Is No Reason For Excitement
China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.
National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
Investors Give Wai Yuen Tong Medicine Holdings Limited (HKG:897) Shares A 46% Hiding
